[Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin]
Zhonghua Xue Ye Xue Za Zhi
.
2023 Jan 14;44(1):81-86.
doi: 10.3760/cma.j.issn.0253-2727.2023.01.018.
[Article in Chinese]
Authors
M C Cai
1
,
P P Xu
1
,
W L Zhao
1
Affiliation
1
National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China.
PMID:
36987732
PMCID:
PMC10067377
DOI:
10.3760/cma.j.issn.0253-2727.2023.01.018
No abstract available
MeSH terms
Antineoplastic Agents*
Brentuximab Vedotin
Humans
Immunoconjugates* / therapeutic use
Ki-1 Antigen
Lymphoma* / drug therapy
Substances
Brentuximab Vedotin
Ki-1 Antigen
Antineoplastic Agents
Immunoconjugates